William D. Baird III Sells 10,000 Shares of Amicus Therapeutics, Inc. (FOLD) Stock
Amicus Therapeutics, Inc. (NASDAQ:FOLD) CFO William D. Baird III sold 10,000 shares of the business’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $14.72, for a total transaction of $147,200.00. Following the transaction, the chief financial officer now owns 105,121 shares of the company’s stock, valued at $1,547,381.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) traded down $0.23 during trading on Thursday, hitting $15.44. 1,676,325 shares of the stock traded hands, compared to its average volume of 2,419,200. Amicus Therapeutics, Inc. has a twelve month low of $5.07 and a twelve month high of $16.60. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.22 and a current ratio of 6.32. The stock has a market cap of $2,570.00, a PE ratio of -8.44 and a beta of 1.72.
Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.10). Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The firm had revenue of $10.90 million during the quarter, compared to analysts’ expectations of $9.02 million. During the same period last year, the company earned ($0.33) EPS. The business’s quarterly revenue was up 419.0% on a year-over-year basis. research analysts forecast that Amicus Therapeutics, Inc. will post -1.56 earnings per share for the current year.
Several research analysts recently weighed in on the stock. JPMorgan Chase & Co. restated an “overweight” rating on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. Chardan Capital reaffirmed a “buy” rating and set a $16.50 price objective (down previously from $17.50) on shares of Amicus Therapeutics in a research note on Wednesday, September 13th. Zacks Investment Research raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a research note on Tuesday, October 10th. Cowen reaffirmed an “outperform” rating and set a $18.00 price objective (up previously from $16.00) on shares of Amicus Therapeutics in a research note on Thursday, September 14th. Finally, Robert W. Baird reaffirmed an “outperform” rating and set a $18.00 price objective (up previously from $16.00) on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $17.81.
TRADEMARK VIOLATION NOTICE: “William D. Baird III Sells 10,000 Shares of Amicus Therapeutics, Inc. (FOLD) Stock” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2018/01/04/william-d-baird-iii-sells-10000-shares-of-amicus-therapeutics-inc-fold-stock.html.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.